首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution
【24h】

Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution

机译:CYP2C19 * 2基因突变伴气虚血瘀证的志愿者中补充心辛通与氯吡格雷比较

获取原文
获取外文期刊封面目录资料

摘要

This study was to determine the impact of adjunctive Buchang Naoxintong Jiaonang (BNJ) to clopidogrel on volunteers with the CYP2C19*2 gene mutation accompanied with qi deficiency and blood stasis (QDBS) constitution. Eighteen males with QDBS constitution were selected, who were 6 CYP2C19*1/*1, 6 CYP2C19*1/*2, and 6 CYP2C19*2/*2, and signed informed consent. Results showed that the maximal platelet aggregation (Aggmax) and 5 min aggregation (Agglate) with 5-μmol/L ADP in three different CYP2C19*2 genotypes were significantly decreased after any drug therapy compared with corresponding baseline measurements (all valuesP<.05). But percent inhibitions of Aggmaxand Agglate(IPAs) in CYP2C19*2/*2 genotype at 4 hours, 24 hours, 3 days, and 7 days after clopidogrel administration were all the lowest among three CYP2C19*2 genotypes (P<.01), and IPAs in CYP2C19*1/*2 genotype were between CYP2C19*1/*1 and CYP2C19*2/*2. IPAs had no significant difference among three different CYP2C19*2 genotypes after BNJ or adjunctive BNJ. In addition, changes of CD62P, PAC1, and sCD40L were similar to changes of ADP-induced platelet aggregation in three different CYP2C19*2 genotypes. Conclusion was that adjunctive BNJ to clopidogrel can enhance the antiplatelet effect in volunteers with the CYP2C19*2 gene mutation.
机译:这项研究的目的是确定辅助性的Buchang Naoxintong Jiaonang(BNJ)对氯吡格雷对具有CYP2C19 * 2基因突变并伴有气虚血瘀(QDBS)构成的志愿者的影响。选择18名具有QDBS体质的男性,分别为6 CYP2C19 * 1 / * 1、6 CYP2C19 * 1 / * 2和6 CYP2C19 * 2 / * 2,并签署知情同意书。结果显示,在3种不同CYP2C19 * 2基因型中,5-μmol/ L ADP的最大血小板聚集(Aggmax)和5μmin聚集(Agglate)与相应的基线测量值相比,任何药物治疗后均显着降低(所有值P <.05) 。但是在服用氯吡格雷后4小时,24小时,3天和7天,CYP2C19 * 2 / * 2基因型对Aggmax和Agglate(IPAs)的抑制百分比在三种CYP2C19 * 2基因型中均最低(P <.01), CYP2C19 * 1 / * 2基因型的IPA和IPA在CYP2C19 * 1 / * 1和CYP2C19 * 2 / * 2之间。 BNJ或辅助BNJ后三种不同CYP2C19 * 2基因型的IPA无显着差异。此外,在三种不同的CYP2C19 * 2基因型中,CD62P,PAC1和sCD40L的变化与ADP诱导的血小板聚集的变化相似。结论是BNJ与氯吡格雷的辅助作用可增强CYP2C19 * 2基因突变志愿者的抗血小板作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号